| BLDR |
Report |
Q2 2026 adjusted EBITDA |
MISS |
pred ~$315M vs. cons $325M |
MEDIUM |
| BLDR |
Report |
Q2 2026 net sales |
IN-LINE |
pred ~$3.90B vs. cons $3.92B |
MEDIUM |
| BLDR |
Report |
Q2 2026 adjusted EPS |
MISS |
pred ~$1.21 vs. cons $1.29 |
MEDIUM |
| BLDR |
Guide |
FY2026 adjusted EBITDA |
LOWER |
guide ~$1.18B vs. cons $1.217B (FY2026) |
MEDIUM |
| BLDR |
Guide |
FY2026 net sales |
LOWER |
guide ~$14.70B vs. cons $14.817B (FY2026) |
MEDIUM |
| BLDR |
Guide |
FY2026 free cash flow |
LOWER |
guide ~$400M vs. cons $480M (FY2026) |
MEDIUM |
| BLDR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-6.0% |
— |
MEDIUM |
| BLDR |
Return |
5-day cumulative residual |
-8.0% (FOLLOW-THROUGH) |
FY2026 adjusted EBITDA guidance of ~$1.18B vs. $1.217B consensus and free-cash-flow guidance of ~$400M vs. $480M consensus imply lower second-half margins and estimate revisions, extending the day-1 residual decline from ~-6.0% to ~-8.0% cumulatively by day 5. |
MEDIUM |